NightHawk Biosciences, Inc., (NHWK) News
Filter NHWK News Items
NHWK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NHWK News Highlights
- For NHWK, its 30 day story count is now at 3.
- Over the past 9 days, the trend for NHWK's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about NHWK are CDMO and DEC.
Latest NHWK News From Around the Web
Below are the latest news stories about NIGHTHAWK BIOSCIENCES INC that investors may wish to consider to help them evaluate NHWK as an investment opportunity.
NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research UniversityNext phase of multi-million-dollar project to include scaling up cGMP manufacturing for phase 1 trial targeting infectious disease CDMO services attracting considerable interest as state-of-the-art San Antonio facility helps address industry-wide scarcity for large molecule manufacturing DURHAM, N.C., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announc |
NightHawk Biosciences Announces Major Milestone with Completion of Manufacturing Run for a Premier U.S.-Based Biopharmaceutical CompanyManufacturing run at Scorpius’ state-of-the-art San Antonio microbial facility sets the stage for commercial manufacturing Advances multi-million dollar biomanufacturing contract awarded earlier this year; set to expand upon client’s regulatory filing and start of commercial manufacturing DURHAM, N.C., Dec. 18, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announ |
NightHawk Biosciences Announces Strategic Shift into a Pure-Play Large Molecule Biomanufacturing CDMO to Capitalize on Rapid Growth in Sales Pipeline along with Divestiture of Non-Core AssetsOver $20 million in signed manufacturing contracts which includepremier biotech/pharma companies and research institutes Elusys divestiture and R&D cuts expected to eliminate over $40 million in commitments and reduce operating expenses by more than $13 million per year DURHAM, N.C., Dec. 12, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) today (“NightHawk” or the “Company”) announced its strategic shift into a pure-play biomanufacturing Contract Development & Manufacturing |
NightHawk Biosciences Provides Q3 2023 Business UpdateDURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, and commercialization of innovative therapies, today provided strategic, financial, and operational updates for the quarter ended September 30, 2023. Jeff Wolf, Chief Executive Officer of NightHawk, commented, “We are very pleased with the progress of our Scorpius San Antonio facility where operations |
NHWK: 2Q:23 ResultsBy John Vandermosten, CFA NYSE:NHWK READ THE FULL NHWK RESEARCH REPORT NightHawk Biosciences, Inc. (NYSE:NHWK) reported 2Q:23 results in mid-August as presented in a press release and in the filing of its Form 10-Q . Since our previous update in May, it has been quiet; however, Scorpius has continued to generate revenues and is developing its process development activities. In April, the final |
Morrisville CEO pitches to buy his company's subsidiary for $45M+The CEO of a pharmaceutical company in Morrisville wants to buy the firm's own subsidiary as operating cash runs low. |
NightHawk Biosciences Provides Q2 2023 Business UpdateDURHAM, N.C., Aug. 14, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, and commercialization of innovative medical countermeasures that combat unmet and emerging biothreats, today provided strategic, financial, and operational updates for the quarter ended June 30, 2023. Jeff Wolf, Chief Executive Officer of NightHawk, commented, “Development of our biomanufacturing opera |
NHWK: First Scorpius RevenuesBy John Vandermosten, CFA NYSE:NHWK READ THE FULL NHWK RESEARCH REPORT NightHawk Biosciences, Inc. (NYSE:NHWK) reported 1Q:23 results on May 15, 2023 in a press release and in the filing of its Form 10-Q . Since our previous update in April, it has been quiet; however, first revenues have been generated from Scorpius and the final payment from the Cancer Prevention and Research Institute of Texas |
NightHawk Biosciences Provides Q1 2023 Business UpdateDURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, and commercialization of innovative medical countermeasures that combat unmet and emerging biothreats, today provided strategic, financial, and operational updates for the quarter ended March 31, 2023. Jeff Wolf, Chief Executive Officer of NightHawk, commented, “We continue to invest in and advance our |
NHWK: ANTHIM Sales Boost RevenuesBy John Vandermosten, CFA NYSE:NHWK READ THE FULL NHWK RESEARCH REPORT NightHawk Biosciences, Inc. (NYSE:NHWK) reported 2022 results on March 31, 2023 in a press release and in its filing of Form 10-K . It has been a year of transition for the company as it made an acquisition, expanded its manufacturing efforts, converted into a vertically integrated biosciences company and executed several |